DoD Prostate Cancer Population Science Impact Award

Funding Opportunity Number: W81XWH-14-PCRP-PSIA Opportunity Category: DiscretionaryFunding Instrument Type: Cooperative AgreementGrantCategory of Funding Activity: Science and Technology and other Research and DevelopmentCFDA Number: 12.420Eligible Applicants Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"Agency Name: DOD-AMRAAClosing Date: Oct 29, 2014Award Ceiling: $0Expected Number of Awards: 3Creation Date: May 30, 2014Funding Opportunity Description: The PCRP Population Science Impact Award mechanism was first offered as the Population-Based Idea Development Award in FY09 and the Population-Based Research Award in FY10 and FY11. Since then, 62 applications have been received, and 4 have been recommended for funding. The Population Science Impact Award mechanism supports high-impact, population science approaches to prostate cancer research. Applications should clearly demonstrate the potential of the study to contribute significantly to the elimination of death from prostate cancer and/or enhancing the well-being of men experiencing the impact of the disease. As such, studies should address one of the PCRP overarching challenges, or, alternatively, justify the study as addressing another critical area in prostate cancer research. In addition, studies are expected to address one or more of the PCRP focus areas; for the Population Science Impact Awa...
Source: - Category: Research Tags: Science and Technology and other Research and Development Source Type: funding

Related Links:

Cascante M Abstract Platinum-based chemotherapy persists to be the only effective therapeutic option against a wide variety of tumours. Nevertheless, the acquisition of platinum resistance is utterly common, ultimately cornering conventional platinum drugs to only palliative in many patients. Thus, encountering alternatives that are both effective and non-cross-resistant is urgent. In this work, we report the synthesis, reduction studies and luminescent properties of a series of cyclometallated (C,N,N') PtIV compounds derived from amine-imine ligands, and their remarkable efficacy at the high nanomolar range and ...
Source: Chemistry - Category: Chemistry Authors: Tags: Chemistry Source Type: research
ConclusionsMaxillofacial manifestation of bone metastasis is common but is often overlooked. Therefore, it should be considered in the differential diagnosis when a patient with a history of antiresorptive medications presents with a gingival mass and/or exophytic bone. Good clinical judgment and well-timed bone biopsy and diagnostic imaging can lead to the correct diagnosis and optimal treatment.
Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology - Category: ENT & OMF Source Type: research
CONCLUSION: Treatment with 177Lu-PSMA has emerged as a promising systemic modality, which involves the delivery of targeted radiation therapy in the form of β-particles to sites of tumour tissue. Therapy is provided on an outpatient basis, is well tolerated with relatively few side effects and has a positive effect on overall survival and quality of life. At present, it is used mostly in the setting of advanced, castrate-resistant cancer. Patients are selected (amongst other criteria) based on the prior PSMA-based SPECT/PET/CT imaging (99mTc-,68Ga- or 18F-PSMA), which should demonstrate sufficient receptor expression ...
Source: South African Journal of Surgery - Category: Surgery Tags: S Afr J Surg Source Type: research
ConclusionClinical interventions for improving symptoms should focus particularly on the first year after prostate cancer diagnosis. Greater emphasis on improving sexual function should be practiced in clinical and rehabilitative care, since this area has the single greatest impact on symptom-specific QoL after primary treatment for prostate cancer.
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: In France, end-of-life management of men with PCa, regardless of the cause of death, is centered on SSH and HPC, essentially at the time of death. Certain indicators of end-of-life management were particular high. LEVEL OF EVIDENCE: 4. PMID: 31708329 [PubMed - as supplied by publisher]
Source: Progres en Urologie - Category: Urology & Nephrology Tags: Prog Urol Source Type: research
Prostate Cancer and Prostatic Diseases, Published online: 04 November 2019; doi:10.1038/s41391-019-0183-9Temporal trends and social barriers for inpatient palliative care delivery in metastatic prostate cancer patients receiving critical care therapies
Source: Prostate Cancer and Prostatic Diseases - Category: Urology & Nephrology Authors: Source Type: research
AbstractPurposeThe goal of the present study was to determine factors related to a ceiling effect (CE) on the EQ-5D-5L among Japanese patients with prostate cancer (PC).MethodsAn existent cross-sectional observational study dataset was used. Patients were  ≥ 20 years of age and diagnosed with PC. For CE determinants on the EQ-5D-5L, we excluded possible “full-health” patients flagged by the EQ-VAS (score = 100) and/or FACT-P (score = 156) instruments. We then divided them into binary variables: A CE group (EQ-5D-5L score = 1) a nd others (
Source: Quality of Life Research - Category: Health Management Source Type: research
ConclusionsThis study supports previous findings that higher performance status, cancer diagnosis and higher baseline pain intensity predict analgesic RT response. The study presents new data showing that presence of soft tissue expansion predicts RT response and that CRP is not significantly associated with analgesic RT response.Clinical trial identificationNCT02107664 (Date of registration April 8, 2014).Legal entity responsible for the studyP ål Klepstad.FundingThe European Palliative Care Research Centre (PRC).DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
Conclusion: 68Ga-PSMA PET/CT is cost-effective in all patients with regard to avoidance of incorrect treatment. It enabled new curative options for patients with previous radiotherapy who are usually treated palliatively. Therefore, 68Ga-PSMA PET/CT staging should become standard for BCR after surgery with or without radiotherapy.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Clinical Source Type: research
This study investigates whether robot-assisted sLND is associated with better peri-operative outcomes compared to the open approach. Early oncological outcomes are also compared. Patients and methods: In this retrospective study, clinical data were collected from 60 patients undergoing open sLND between 2010-2016 and 30 patients undergoing robot-assisted sLND between 2016 and 2018 at our tertiary referral center. The primary objective of the study was to compare peri-operative outcomes (length of stay, estimated blood loss, operative time, intra-operative and postoperative complications) and LN yield between both pro...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Databases & Libraries | Epidemiology | Funding | Genetics | Grants | Health | Palliative | Palliative Care | Prostate Cancer | Research | Science | Statistics | Study